Page last updated: 2024-11-06

octenidine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Octenidine dihydrochloride is a synthetic, broad-spectrum antiseptic with a long history of use in various medical applications, including wound care, skin disinfection, and oral hygiene. Its effectiveness stems from its ability to disrupt bacterial cell membranes, leading to cell death. Octenidine is characterized by its potent bactericidal activity against a wide range of microorganisms, including Gram-positive and Gram-negative bacteria, fungi, and enveloped viruses. It is notable for its low toxicity profile, making it suitable for topical application and use in sensitive areas. Octenidine's mechanism of action involves binding to the cell membrane of bacteria, leading to disruption of the membrane's integrity and ultimately cell death. It is noteworthy that octenidine is a relatively new antiseptic, and its effectiveness against emerging antibiotic-resistant strains is an ongoing area of research. The compound's long-term effects and potential for environmental impact are also subjects of investigation. Octenidine's broad-spectrum activity, low toxicity, and proven efficacy have made it a valuable antiseptic in a variety of medical settings. Its continued research and development focus on optimizing its application, exploring its potential against antibiotic-resistant strains, and assessing its long-term effects.'

Cross-References

ID SourceID
PubMed CID51167
CHEMBL ID1199480
CHEBI ID135826
SCHEMBL ID124821
MeSH IDM0105602

Synonyms (34)

Synonym
octenidine
octenidine [inn:ban]
octenidina [inn-spanish]
1-octanamine, n,n'-(1,10-decanediyldi-1(4h)-pyridinyl-4-ylidene)bis-
1,1'-decamethylebis-(1,4-dihydro-4-(octaimino)pyridin) (iupac)
octenidinum [inn-latin]
CHEBI:135826
71251-02-0
D08289
octenidine (inn)
n-octyl-1-[10-(4-octyliminopyridin-1-yl)decyl]pyridin-4-imine
CHEMBL1199480
unii-oze0372s5a
octenidina
octenidinum
oze0372s5a ,
FT-0630803
AKOS015900152
octenidine [who-dd]
octenidine [mi]
octenidine [inn]
las-41003 component octenidine
SCHEMBL124821
DTXSID70221427
n,n'-(1,1'-(decane-1,10-diyl)bis(pyridin-1(1h)-yl-4(1h)-ylidene))bis(octan-1-amine)
octenidin
A914602
DB12624
n,n'-(1,1'-(decane-1,10-diyl)bis(pyridin-1(1h)-yl-4(1h)-ylidene))dioctan-1-amine
win41464;win-41464;win 41464
Q27285931
CS-0020931
HY-B2170
n-(1-{10-[4-(octylimino)-1,4-dihydropyridin-1-yl]decyl}-1,4-dihydropyridin-4-ylidene)octan-1-amine

Research Excerpts

Overview

Octenidine (OCT) is a widely used antiseptic molecule with an antimicrobial spectrum covering a broad range of bacteria and fungi. Octenidine is a promising alternative agent which could be more effective against Gram-negative organisms.

ExcerptReferenceRelevance
"Octenidine/carbenicillin is a novel group of uniform materials based on organic salts (GUMBOS) with inherent in vitro antibacterial activity that comes from its parent antiseptic and antibacterial ions, octenidine and carbenicillin, respectively."( Octenidine/carbenicillin GUMBOS as potential treatment for oropharyngeal gonorrhoea.
Hobden, JA; Lopez, KM; Warner, IM, 2020
)
2.72
"Octenidine (OCT) is a widely used antiseptic molecule with an antimicrobial spectrum covering a broad range of bacteria and fungi. "( Octenidine: Novel insights into the detailed killing mechanism of Gram-negative bacteria at a cellular and molecular level.
Lohner, K; Malanovic, N; Ön, A; Pabst, G; Zellner, A, 2020
)
3.44
"Octenidine is a promising alternative agent which could be more effective against Gram-negative organisms."( EFFECT of daily antiseptic body wash with octenidine on nosocomial primary bacteraemia and nosocomial multidrug-resistant organisms in intensive care units: design of a multicentre, cluster-randomised, double-blind, cross-over study.
Brosteanu, O; Chaberny, IF; Hasenclever, D; Meißner, A, 2017
)
1.44

Effects

ExcerptReferenceRelevance
"Octenidine (OCT) has become a widely used antiseptic in professional wound care, but its influence on several components of the wound healing process remains unclear."( The Antiseptic Octenidine Inhibits Langerhans Cell Activation and Modulates Cytokine Expression upon Superficial Wounding with Tape Stripping.
Elbe-Bürger, A; Kienzl, P; Matiasek, J; Nikolić, N; Tajpara, P; Vierhapper, M, 2019
)
1.59

Treatment

ExcerptReferenceRelevance
"Octenidine treatments reduced the proportions of motile forms in samples of subgingival plaque and also restricted its ability to produce H2S."( Effects of octenidine on dental plaque and gingivitis in monkeys.
Kennedy, JB; Little, WA; Mirth, DB; Shern, RJ, 1987
)
1.38

Toxicity

ExcerptReferenceRelevance
" Octenisept seems to have a toxic effect in non-distinguished tissue."( [Severe side effects after Octenisept irrigation of penetrating wounds in children].
Habenicht, R; Hülsemann, W, 2009
)
0.35
" However, little is known about their potential toxic properties."( [A comparative in vitro study of cell toxicity of clinically used antiseptics].
Goertz, O; Hirsch, T; Jacobsen, F; Niederbichler, A; Rittig, A; Seipp, HM; Steinau, HU; Steinstraesser, L, 2009
)
0.35
"Lavasept showed only slight to moderate toxic effects on cellular vitality and proliferation."( [A comparative in vitro study of cell toxicity of clinically used antiseptics].
Goertz, O; Hirsch, T; Jacobsen, F; Niederbichler, A; Rittig, A; Seipp, HM; Steinau, HU; Steinstraesser, L, 2009
)
0.35
" Furthermore, antimicrobial efficacy and toxic properties must be included in the clinical decision process for optimal therapy of chronic wounds."( [A comparative in vitro study of cell toxicity of clinically used antiseptics].
Goertz, O; Hirsch, T; Jacobsen, F; Niederbichler, A; Rittig, A; Seipp, HM; Steinau, HU; Steinstraesser, L, 2009
)
0.35
"The degree of toxicity varied between octenidine dihydrochloride and chlorhexidine gluconate, with chlorhexidine gluconate being less toxic than octenidine dihydrochloride at the same concentration."( Cytotoxic effects of different mouthwash solutions on primary human articular chondrocytes and normal human articular cartilage - an in vitro study.
Cai, X; Cucchiarini, M; Hannig, M; Madry, H; Reda, B; Schmitt, G; Venkatesan, JK, 2023
)
1.18

Compound-Compound Interactions

ExcerptReferenceRelevance
" The study confirms that MRSA can be eradicated by means of washing with an antiseptic combined with mupirocin treatment."( Eradication of MRSA from carriers by means of whole-body washing with an antiseptic in combination with mupirocin nasal ointment.
Höffler, U; Siebert, J; Sloot, N, 1999
)
0.3
" Decolonization was performed by intranasal application of mupirocin, combined with an octenidine dihydrochloride bodywash over a period of five days."( Methicillin-resistant Staphylococcus aureus whole-body decolonization among hospitalized patients with variable site colonization by using mupirocin in combination with octenidine dihydrochloride.
Gatermann, S; Mueller, C; Muhr, G; Rohr, U; Wilhelm, M, 2003
)
0.74
" The aim of this study is to find new options for preventing infection by using alternative adjuvants in combination with PMMA."( Octenidine in combination with polymethylmethacrylate: a new option for preventing infection?
Bischoff, M; Braunwarth, H; Gebhard, F; Goroncy-Bermes, P; Möricke, A; Weckbach, S, 2012
)
1.82

Bioavailability

ExcerptReferenceRelevance
"For 2-phenoxyethanol the systemic impact of the high absorption rate and a potential toxicological risk have to be investigated in further studies."( The percutaneous permeation of a combination of 0.1% octenidine dihydrochloride and 2% 2-phenoxyethanol (octenisept®) through skin of different species in vitro.
Braun, M; Kietzmann, M; Siebert, J; Stahl, J, 2011
)
0.62

Dosage Studied

ExcerptRelevanceReference
" A systemic effect cannot be observed upon oral application within large of dosage scales."( [Octenidine dihydrochloride, properties of a new antimicrobial agent].
Harke, HP, 1989
)
1.19
" The potential benefits of new chemical devices for periodontal therapy, include improved patient compliance, an easier access to periodontal pocket and a lower dosage of antimicrobial agent."( Zinc plus octenidine: a new formulation for treating periodontal pathogens. A single blind study.
Bignozzi, CA; Candotto, V; Carinci, F; Cura, F; Lauritano, D; Pazzi, D; Tagliabue, A; Tettamanti, L,
)
0.53
" Therefore, dosing for the antimicrobial mouthwash ingredients administration would ideally be determined to remain below IC50."( Cytotoxic effects of different mouthwash solutions on primary human articular chondrocytes and normal human articular cartilage - an in vitro study.
Cai, X; Cucchiarini, M; Hannig, M; Madry, H; Reda, B; Schmitt, G; Venkatesan, JK, 2023
)
0.91
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
dihydropyridine
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (5)

Assay IDTitleYearJournalArticle
AID210413Chlorohexidine coefficient for Streptococcus sobrinus 6715-131988Journal of medicinal chemistry, Oct, Volume: 31, Issue:10
The in vitro dental plaque inhibitory properties of a series of N-[1-alkyl-4(1H)-pyridinylidene]alkylamines.
AID9436Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient1988Journal of medicinal chemistry, Oct, Volume: 31, Issue:10
The in vitro dental plaque inhibitory properties of a series of N-[1-alkyl-4(1H)-pyridinylidene]alkylamines.
AID9431Chlorohexidine coefficient for Actinomyces viscosus M-1001988Journal of medicinal chemistry, Oct, Volume: 31, Issue:10
The in vitro dental plaque inhibitory properties of a series of N-[1-alkyl-4(1H)-pyridinylidene]alkylamines.
AID210414Minimal bactericidal concentration against Streptococcus sobrinus 6715-131988Journal of medicinal chemistry, Oct, Volume: 31, Issue:10
The in vitro dental plaque inhibitory properties of a series of N-[1-alkyl-4(1H)-pyridinylidene]alkylamines.
AID210417Plaque bactericidal index against Streptococcus sobrinus 6715-13 measured as chlorohexidine coefficient1988Journal of medicinal chemistry, Oct, Volume: 31, Issue:10
The in vitro dental plaque inhibitory properties of a series of N-[1-alkyl-4(1H)-pyridinylidene]alkylamines.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (259)

TimeframeStudies, This Drug (%)All Drugs %
pre-199012 (4.63)18.7374
1990's12 (4.63)18.2507
2000's33 (12.74)29.6817
2010's141 (54.44)24.3611
2020's61 (23.55)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 47.31

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index47.31 (24.57)
Research Supply Index5.75 (2.92)
Research Growth Index5.27 (4.65)
Search Engine Demand Index110.30 (26.88)
Search Engine Supply Index2.99 (0.95)

This Compound (47.31)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials40 (14.65%)5.53%
Reviews8 (2.93%)6.00%
Case Studies35 (12.82%)4.05%
Observational2 (0.73%)0.25%
Other188 (68.86%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (14)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Phase IIa, Two-center, Randomized, Double Blind Study With Parallel Groups to Evaluate the Anti-mycotic and Anti-inflammatory Efficacy of Topical Combinational Product LAS 41003 Versus Corresponding Mono-substances in Patients With Inflammatory Tinea Pedi [NCT01096472]Phase 2120 participants (Actual)Interventional2010-02-28Completed
A Randomized Single Center Blinded Clinical Evaluation of the Antimicrobial Effectiveness of an Antimicrobial Cloth Compared to Vehicle and 0.9% Saline [NCT03229759]Phase 299 participants (Actual)Interventional2017-06-21Completed
Phase II Study to Assess Bacterial Count Reduction of Three Octenidine Mouthwash Concentrations in Comparison to a Placebo in Patients With Mild Gingivitis [NCT02138552]Phase 290 participants (Actual)Interventional2013-10-31Completed
Randomized, Placebo-controlled, Parallel Group, Double-blind, Multi-center Phase III Study to Assess the Inhibition of Plaque Formation of 0.1% Octenidine Mouthwash vs Placebo in Subjects With a Gingival Index ≤1.5 [NCT03322124]Phase 3100 participants (Actual)Interventional2018-01-22Completed
Phase IIa, Two-centre, Randomized, Double Blind Study to Evaluate the Anti-mycotic and Anti-inflammatory Efficacy of Topical Combinational Product LAS41003 Versus Corresponding Mono-substances in Patients With Candida Infections in Intertriginous Areas at [NCT01102387]Phase 2137 participants (Actual)Interventional2010-02-28Completed
Comparison of Resin Salve and Conventional Octenidine in Patients With Neuropathic Diabetic Foot Ulcers - a Prospective, Randomized and Controlled Clinical Trial [NCT02169167]35 participants (Actual)Interventional2014-06-30Completed
Explorative, Double-blind, Randomized, Controlled Multi-center Phase II Study to Evaluate the Efficacy and Safety of Topically Applied LAS41003 Once Daily Versus LAS189962 and LAS189961 in the Treatment of Superficial Infected Eczema [NCT01020994]Phase 2150 participants (Anticipated)Interventional2009-11-30Completed
Antiseptic-coated Intermittent Urinary Catheter: Efficacy and Feasibility of Neurogenic Bladder Management and Prevention of Catheter-associated Urinary Tract Infections in Children [NCT02697162]Phase 2/Phase 30 participants (Actual)Interventional2016-06-30Withdrawn(stopped due to Withdrawal of research institution from participating)
Randomized, Double-blind, Single-center, Placebo-controlled Study to Evaluate the Efficacy of Octenisept® in Patients With Chronic Wounds [NCT01434914]Phase 49 participants (Actual)Interventional2011-10-31Terminated(stopped due to early termination due to poor recruitment)
Skin Disinfection With Octenidine Dihydrochloride for the Prevention of Catheter-Associated Infections - A Double-Blind, Randomized, Controlled Trial [NCT00515151]Phase 4400 participants (Actual)Interventional2002-05-31Completed
The Significance of the Skin Microbiome in the Pathophysiology of Polymorphic Light Eruption [NCT04985526]30 participants (Anticipated)Interventional2021-05-07Recruiting
Clinical Relevance of the Antimicrobial Resistance Testing in the Treatment of Chronic Wounds With Antiseptics [NCT04172363]Phase 30 participants (Actual)Interventional2020-07-22Withdrawn(stopped due to PI left site)
Open, Blindly Evaluated, Prospective, Controlled, Randomized, Multicenter Phase III Clinical Trial to Compare Intra-individually the Efficacy and Tolerance of Oleogel-S10 Versus Standard of Care in Accelerating the Healing of Grade 2a Partial-Thickness Bu [NCT01657292]Phase 361 participants (Actual)Interventional2012-08-31Completed
Randomized, Placebo-controlled, Parallel Group, Double-blind, Multi-center Phase III Study to Assess the Inhibition of Plaque Formation of 0.1% Octenidine Mouthwash vs Placebo in Subjects With a Gingival Index ≤1.5 [NCT03378401]Phase 3114 participants (Actual)Interventional2018-01-11Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT01657292 (1) [back to overview]Percentage of Patients With Earlier Healing of the Wound Half Treated With Oleogel-S10 Compared to the Wound Half Receiving Standard of Care
NCT03229759 (1) [back to overview]Bacterial Count at 10 Minutes Post Application

Percentage of Patients With Earlier Healing of the Wound Half Treated With Oleogel-S10 Compared to the Wound Half Receiving Standard of Care

Photo-based evaluation by independent experts blinded to the treatment regime. (NCT01657292)
Timeframe: 2 to 3 weeks

Interventionpercentage of patients (Number)
Entire Study Population85.7

[back to top]

Bacterial Count at 10 Minutes Post Application

(NCT03229759)
Timeframe: 10 minutes after application of test product

,,
Interventionlog10 CFU/cm^2 (Mean)
Abdomen- BaselineAbdomen- 10 minutesGroin- BaselineGroin- 10 minutes
Investigational Product3.551.195.952.98
Saline Control3.612.646.074.90
Vehicle Control3.662.565.894.25

[back to top]